

Originalarbeiten

1. Fenchel K, Bergmann L., Jahn B., Mitrou P.S.: Modulation of adhesion molecules in patients with AML during immunotherapy with interleukin-2.
In: Haematology and Blood Transfusion. Acute leukemias IV (Hiddemann et al., ed.), Springer Verlag, Heidelberg (1993), 90-95
2. Fenchel K., Bergmann L., Jahn B., Mitrou P.S.: Upregulation of adhesion molecules by immunotherapy as a mechanism of cytotoxicity in renal cell cancer, malignant melanoma, and acute myelocytic leukemia.
In: Bergmann L., Mitrou P.S. (eds.) Contributions to Oncology: Cytokines in Cancer Therapy. Karger Verlag, Basel (1994), 336-346
3. Fenchel K., Wijermans P., Mitrou P.S., Hoelzer D., Bergmann L.: Fludarabine is an effective agent in immunocytic lymphoma. *Onkologie* 17 (1994), 508-513
4. Fenchel K., Heller C., Weidmann E., Wörmann B., Brieger J., Ganser A., Mitrou P.S., Bergmann L., Hoelzer D.: Expression of CD7 and CD15 on leukemic blasts are prognostic parameters in patients with acute myelocytic leukemia-irrelevance of CD34
Acute leukemias V (Hiddemann et al., ed.), Springer Verlag, Heidelberg (1995) 536-541
5. Fenchel K., Bergmann L., Wijermans P., Engert A., Pralle H., Mitrou P.S., Diehl V., Hoelzer D.: Clinical experience with fludarabine and its immunosuppressive effects in pretreated chronic lymphocytic Leuk. *Lymphoma*, 18 (1995) 485-492
6. Bergmann L., Fenchel K., Jahn B., Mitrou P.S., Hoelzer D.:
Immunosuppressive effects and clinical response of fludarabine in refractory chronic lymphocytic leukemia.
Ann. Oncol. 4 (1993), 371-375
7. Fenchel K.: Hämatologie-Onkologie. In: Almeling M., Böhm F. (eds.)
Tauchmedizin. Ecomed Verlag, 1998 chapter II 7.4.7, 1-15
8. Fenchel K., Karthaus M.: Cytotoxic Drug Extravasation. *Antibiotics and Chemotherapy* Vol. 50, Karger Verlag (1999) 144-148
9. Göke B., Fenchel K., Knobloch S., Arnold R., Adler G.: Increased CCK-response to proteinase inhibitor feeding after induction of pancreatic hypertrophy in rats. *Pancreas* (1988) 3; 5: 576-579

10. Fenchel K., Karthaus M.: Zytostatika Paravasate- Prävention und Therapie. MMW, 2001, 3/4: 44-46
11. Bergmann L., Fenchel K., Neugebauer T., Jahn B., Enzinger HM., Jonas D., Mitrou P.S.: Daily alternating administration of interferon-alpha and interleukin-2 bolus infusion in two different dose levels in metastatic renal cell cancer – results of two phase II studies.
In: Bergmann L., Mitrou P.S. (eds.) Contributions to Oncology: Cytokines in Cancer Therapy. Karger Verlag, Basel (1994), 201-210
12. Bergmann L., Fenchel K., Enzinger HM., Weidmann E., Jahn B., Jonas D., Mitrou P.S.: Daily alternating application of high dose interferon-alpha and interleukin-2 bolus infusions in metastatic renal cell carcinoma. Cancer, 72 (1993), 1733-1742
13. Kemkes-Matthes B., Fenchel K., Matzdorff A.: Gerinnungsstörungen als Notfall bei onkologischen Patienten. Der Onkologe (1999) 5, 1083-1089
14. Brieger J., Weidmann E., Fenchel K., Mitrou P.S., Hoelzer D., Bergmann L.: The amplification of the Wilms tumor gene (wt-1) mRNA using the polymerase chain reaction technique may enable sensitive detection of small blast populations in AML. Acute leukemias V (Hiddemann et al., ed.), Springer Verlag, Heidelberg (1995)
15. Brieger J., Weidmann E., Fenchel K., Mitrou P.S., Hoelzer D., Bergmann L.: The expression of the Wilms tumor gene in acute human leukemias as a possible marker for blast cells. Leukemia (1994), 8 (12); 2138-2143
16. Hauck EW., Schmelz HU., Diemer T., Hackstein N., Fenchel K., Weidner W., Knoblauch B.: Epitheloid sarcoma of the penis – a rare differential diagnosis of Peyronie’s diagnose. Int J Impot Res. 2003 Oct;15(5):378-82.
17. Jahn B., Bergmann L, Weidmann E., Brieger J., Fenchel K., Schwulera U., Hoelzer D., Mitrou P.S.: Bone marrow derived T cell clones of previously untreated acute myelocytic leukemia exhibit blast directed autologous cytotoxicity. Leuk. Res. (1995), 19 (2); 73-82

18. **Bergmann L., Weidmann E., Enzinger HM., Fenchel K., Jonas D., Mitrou P.S.: Interleukin-2 and interferon-alpha2b as a daily alternating schedule in advanced renal cell cancer – preliminary results of a phase-II study. World J. Urol., 9 (1991), 215-218**

19. **Weidmann E., Brieger J., Fenchel K., Hoelzer D., Bergmann L., Mitrou P.S.: IL-2 receptor alpha, beta, and gamma chains expressed on blasts of acute myelocytic leukemia may not be functional. Acute leukemias V (Hiddemann et al., ed.), Springer Verlag, Heidelberg (1995)**

20. **Jahn B., Brieger J., Fenchel K., Bergmann L., Mitrou PS.: In vivo regulation of transforming growth factor-beta 1 mRNA in combined cytokine therapy: Interleukin-2 impairs interferon-alpha stimulated increase in transforming growth factor steady state mRNA levels. Cancer Immunol. Immunother. 38 (1994), 304-310**

21. **Duensing S., Schuhknecht S., Fenchel K., Ganser A., Atzpodien J.: Inhibitory effects of Interleukin-12 (IL-12) on spontaneous in vitro apoptosis in B-chronic lymphocytic leukemia (B-CLL). Letter to Blood (1996)**

22. **Borghardt E.J., Kirchertz E.J., Marten I., Fenchel K.: Protein A-immunoadsorption in chemotherapy associated hemolytic-uremic syndrome. Transf. a. Sciences, Vol.19, pp. 5-7 (1998)**

23. **Karthaus M., Südhoff T., Fenchel K., Egerer G., Kämpfe D., Ritter J., Franke A., Heil G., Peters G.: Interventional once daily administration of ceftriaxone in patients with hematological malignancies and febrile neutropenia. WMW 21 (1998), 481-487**

24. **Karthaus M., Südhoff T., Fenchel K., Egerer G., Kämpfe D., Ritter J., Franke A., Heil G., Peters G.: Interventional once daily administration of ceftriaxone in leukaemia and lymphoma patients with febrile neutropenia. Antibiotics and Chemotherapy Vol. 50, Karger Verlag (1999), 26-36**

25. **Hackstein N., Fenchel K., Klett R., Woenckhaus J., Lommel D., Rau W.S.: Multifocal spondylitis after delivery as manifestation of chronic recurrent multifocal osteomyelitis (CRMO): Case report and literature review. Eur. Rad. 2001**

26. **Wagner G, Fenchel K, Back W, Schulz A, Sachse MM.: Leukemia cutis - epidemiology, clinical presentation, and differential diagnoses. JDDG 2012 Jan;10(1):27-36. doi: 10.1111/j.1610-0387.2011.07842.x. Epub 2011 Nov 17**
27. **Göhring K, Wolff J, Doppl W, Schmidt KL, Fenchel K, Pralle H, Sibelius U, Bux J.: Neutrophil CD177 (NB1 gp, HNA-2a) expression is increased in severe bacterial infections and polycythaemia vera. Br J Haematol. 2004 Jul;126(2):252-4**
28. **Fenchel K, Karthaus M.: Cytostatic drug extravasation--are there new recommendations for therapeutic management? Wien Med Wochenschr. 2001;151(3-4):44-6.**
29. **Fenchel K., Rahn S.: Hämatologie In: Tauchtauglichkeit (ed. Tetzlaff K. et al.) Gentner Verlag 2009, 182-201**
30. **Wagner G, Fenchel K, Back W, Schulz A, Sachse MM.: Abheilung Braf assoziierter Keratoakanthome durch Acitrein. JDDG 2013 submitted**
31. **Dempke W., Fenchel K.: Targeted therapy in NSCLC- a double edged sword? EJM 2014 accepted**

Wertung der Arbeiten wie folgt: Die Publikationen 1 – 10 sowie 28 und 29 entstammen meinen ureigensten Arbeiten im Sinne Urheberchaft und Durchführung, die Publikationen 11 – 13, 26-27 und 30-31 beinhalten einen 50 %igen Eigenanteil, 14 – 17 ca. 30 – 40 % und die Arbeiten 18 – 25 ca. 20 %.

Abstacts (Vorträge und Poster)

1. **Fenchel K., Bergmann L., Jahn B., Mitrou P.S., Hoelzer D.: Fludarabinmonophosphat in refractory chronic lymphocytic leukemia. Onkol. 14 Suppl. 2 (1991), 190 (Abstr. 546)**
2. **Fenchel K., Bergmann L., Enzinger H., Jahn B., Weidmann E., Mitrou P.S.: Klinische Ergebnisse und biologische Effekte einer täglich alternierenden Therapie mit Interleukin-2 und Interferon-alpha beim fortgeschrittenen Nierenzellkarzinom. Onkol. 14 Suppl.2 (1991), 40 (Abstr. 112)**
3. **Fenchel K., Bergmann L., Martin H., Jahn B., Mitrou P.S., Hoelzer D.:**

Clinical and biological effects of interleukin-2 as late consolidation therapy in 2nd remission of acute myelocytic leukemia with and without autologous bone marrow transplantation. Haematol. 76 Suppl. 4 (1991), 55 (Abstr. 209)

- 4. Fenchel K., Bergmann L., Jahn B., Mitrou P.S.: Modulation of LFA1-alpha, LFA1-beta, VLA1 and ICAM-1 in vivo by interleukin-2 and alpha-interferon. Cell adhesion molecules in cancer and inflammation, London, 11.-13.12.1991**
- 5. Fenchel K., Bergmann L., Jahn B., Mitrou P.S.: Up-regulation of LFA-1 alpha, LFA 1 beta, VLA-1, and ICAM-1 in vivo by interleukin-2 in patients with AML. Ann. Hematol. 64 Suppl. (1992), Abstr. 131**
- 6. Fenchel K., Jahn B., Bergman L., Mitrou P.S.: Effects of immunotherapy with interleukin-2 and alpha-interferon in patients with malignant melanoma, renal cell carcinoma and AML on adhesion molecules. 8. Frühjahrestagung Dtschl. Ges. Immunol., München, 9.-11.3.1992**
- 7. Fenchel K., Bergmann L., Eder M., Jahn B., Mitrou P.S.: Modulation of adhesion molecules in vivo by interleukin-2 in patients with AML. 2nd Eur.Soc.Analyt.Cell. Pathol. (ESAC 2), Nijmegen, NL, 17.-22.3.1992 Analyt. Cell.Pathol. (1992) 4; 3:155**
- 8. Fenchel K., Jahn B., Bergmann L., Mitrou P.S.: Upregulation of adhesion molecules by immunotherapy as a mechanism of cytotoxicity in renal cell cancer, malignant melanoma and AML. Onkol. 15 (1992), Suppl. 1, 27**
- 9. Fenchel K., Bergmann L., Jahn B., Mitrou P.S.: Effectivity and toxicity of fludarabine phosphate in pretreated advanced chronic lymphocytic leukemia. J. Cancer Res. Clin. Oncol. 118 (1992), R104**
- 10. Fenchel K., Jahn B., Bergmann L., Mitrou P.S.: effects of adhesion molecules of immunotherapy with interleukin-2 and alpha-interferon in patients with malignant melanoma, renal cell cancer and AML. 8th International Congress of Immunology, Budapest, 23. – 28.8.1992**
- 11. Fenchel K., Gencic S., Jahn B., Mitrou P.S., Bergmann L.: Adhesion molecules during immunotherapy in patients with AML, renal cell cancer and malignant melanoma. 24th Congress Intern. Soc. Haematol., London, 23. – 27.8.1992**

12. Fenchel K., Jahn B., Mitrou P.S., Bergmann L.: Fludarabine phosphate in pretreated advanced chronic lymphocytic leukemia – effectivity and immunosuppressive side effects. 24th Congress Intern. Soc. Haematol., London, 23. – 27.8.1992
13. Fenchel K., Bergmann L., Jahn B., Mitrou P.S.: Immunosuppressive effects of fludarabine phosphate in pretreated advanced chronic lymphocytic leukemia. Ann. Hematol. 65 Suppl. (1992), A53
14. Fenchel K., Ernst W., Bergmann L., Jahn B., Ostermann M., Baum R.P., Mitrou P.S.: Complete remission of an allogeneic malignant melanoma acquired by kidney transplantation with immunotherapy of interleukin-2/alpha-Interferon. Ann. Hematol. 65 Suppl. (1992), A53
15. Fenchel K., Gencic S., Jahn B., Mitrou P.S., Bergmann L.: Modulation of adhesion molecules by immunotherapy as a mechanism of cytotoxicity in AML, renal cell cancer, and malignant melanoma. Ann. Hematol. 65 Suppl. (1992), A53
16. Fenchel K., Bergmann L., Neugebauer T., Enzinger H.M., Jahn B., Mitrou P.S., Hoelzer D.: Täglich alternierende Gabe von Interferon-alpha und Interleukin-2 beim metastasierten Nierenzellkarzinom. 6. Hessischer Krebskongress, Bad Homburg, 6. – 8.11.1992
17. Fenchel K., Bergmann L., Jahn B., Mitrou P.S., Hoelzer D.: Effektivität und Toxizität von Fludarabin in der Behandlung der fortgeschrittenen chronisch lymphatischen Leukämie. 6. Hessischer Krebskongress, Bad Homburg, 6. – 8.11.1992
18. Fenchel K., Ernst W., Bergmann L., Jahn B., Ostermann M., Baum R., Mitrou P.S.: Komplette Remission bei einem allogenen malignen Melanom durch IL-2/Interferon-alpha – eine Kasuistik. Med. Klinik 88 Suppl.2 (1993), 178
19. Fenchel K., Bergmann L., Jahn B., Mitrou P.S.: Modulation of adhesion molecules during immunotherapy. 1. Tagung d. Arbeitskreises Adhäsionsmoleküle der Dtsch.

20. Fenchel K., Bergmann L., Brieger J., Jahn B., Mitrou P.S.: Modulation of adhesion molecules (CAM) on lymphocytes by IL-2 and expression of CAM on blasts in patients with AML. Proc. Am. Ass. Cancer Res., 34 (1993) 471 (Abstr. 2811)
21. Fenchel K., Brieger J., Weidmann E., Mitrou P.S., Bergmann L., Hoelzer D.: High expression of ICAM-1 on leucemic cells and upregulation of it's ligands on lymphocytes by IL-2 in patients with AML. Exp. Hematol. 21, (1993), 1119
22. Fenchel K., Bergmann L., Engert A., Mitrou P.S., Diehl V., Hoelzer D.: Clinical results and immunosuppressive effects of fludarabine phosphate in pretreated advanced chronic lymphocytic leukemia – a phase II trial. Ann. Hematol. 67 Suppl. (1993), A30
23. Fenchel K., Bergmann L., Heller C., Christ S., Weidmann E., Brieger J., Mitrou P.S., Hoelzer D.: Prognostic value of simultaneous expression of CD7 and CD33 on leukemic blasts in AML. Ann. Hematol. Suppl. (1993), A30
24. Fenchel K., Bergmann L., Heller C., Christ S., Weidmann E., Brieger J., Mitrou P.S., Hoelzer D.: Prognostic value of simultaneous expression of CD7 and CD33 on leukemic blasts in AML. Blood 82 Suppl. (1993), 122a
25. Fenchel K., Bergmann L., Wijermans P., Engert A., Pralle H., Mitrou P.S., Diehl V., Hoelzer D.: Clinical experience and immunosuppressive effects of fludarabine phosphate in pretreated advanced chronic lymphocytic leukemia – a multicenter trial. Cancer Res. Clin. Oncol. 129 Suppl. (1994) R31

26. Fenchel K., Bergmann L., Heller C., Willmann E., Weidmann E., Brieger J., Mitrou P.S., Hoelzer D.: Prognostic value of surface expression of CD7, CD33, and CD54 on leukemic blasts in AML. *Ann. Hematol.* 68 Suppl. 1 (1994), A21
27. Fenchel K., Bergmann L., Wijermans P., Engert A., Pralle H., Mitrou P.S., Diehl V., Hoelzer D.: Clinical results of fludarabine phosphate in advanced chronic lymphocytic leukemia and non-Hodgkin's lymphoma. *Onkol.* 17 Suppl. 2, (1994), 33
28. Fenchel K., Niermann I., v. Illberg C.: Hörsturz infolge Scuba-Tauchens – eine seltene tauchmedizinische Komplikation. *Jahrestg. d. Dtsch. Ges. f. HNO, Karlsruhe* 29. – 31.05.95
29. Fenchel K., Winkler A., Neugebauer T., Weidmann E., Mitrou P.S., Hoelzer D., Bergmann L.: Clinical results of two high dose daily alternating schedules with interferon-alpha and interleukin-2 in advanced renal cell cancer and malignant melanoma. 3rd International Symposium "Biological Therapy of Cancer" München, 19. – 22.04.95
30. Fenchel K., Hinrichs H.F., Anagnou J., Borghardt E.J.: Klinische Ergebnisse nach fraktionierter Gabe von Cisplatin/5-FU bei inoperablen oder rezidierten Kopf-Halstumoren. 22. Deutscher Krebskongress 20. – 24.02.96 Berlin
31. Fenchel K., Hinrichs H.F., Anagnou J., Borghardt E.J.: Clinical results and side effects with split course application of cisplatin/5-FU in inoperable and/or recurrent head and neck cancer. *Proc. of the American Society of Clinical Oncology ASCO*, 15 (1996), 321
32. Fenchel K., Bergmann L., Wijermans P., Engert A., Pralle H., Mitrou P.S., Diehl V., Hoelzer D.: Clinical results and immunosuppressive effects of fludarabine phosphate in pretreated advanced chronic lymphocytic leukemia and non-Hodgkin's lymphoma. *Brit. J. Haematol.* 87 Suppl. 1, (1994), 167
33. Fenchel K., Bergmann L., Heller C., Willmann E., Weidmann E., Brieger J., Mitrou P.S., Hoelzer D.: Expression of CD7 and CD15 on leukemic blasts has a positive predictive value for response to induction therapy in AML. *Brit. J. Haematol.* 87 Suppl. 1, (1994), 9

34. Fenchel K., Atzpodien J., E. J. Borghardt, R.G. Geissler, H. Kirchner, A. Ganser: Fludarabine and Idarubicin followed by IL-2 in the treatment of pretreated advanced indolent lymphoma – preliminary results of a phase II study. *Exp. Hematology*, 25 (8) (1997), 846
35. Fenchel K., Anagnostou J., Dreher K., Hinrichs H.F., Borghardt E.J.: Klinische Ergebnisse und Nebenwirkungen nach fraktionierter Gabe von Cisplatin/5-FU bei inoperablen oder rezidivierten Kopf-Halstumoren. 6. Interdisziplinäres Onkologisches Symposium, 10. – 12.4.97 Rothenburg o.d.T.
36. Fenchel K., Atzpodien J., E.J. Borghardt, R.G. Geissler, H. Kirchner, A. Ganser: Combination of Fludarabine, Idarubicin, and IL-2 in the treatment of pretreated advanced indolent lymphoma – preliminary results of a phase II study. *Onkologie*, 20, Suppl. 1 (1997), 142
37. Atzpodien J., Fenchel K., R. Hoffmann, E.J. Borghardt, R.G. Geissler, H. Kirchner, A. Ganser: Fludarabine and Idarubicin in the treatment of pretreated advanced indolent lymphoma – results of a phase II study. *Blood* 90 (10), Suppl. 1, 304b
38. Fenchel K., Atzpodien J., E.J. Borghardt, R.G. Geissler, R. Hoffmann, H. Kirchner, A. Ganser: Interleukin-2 is effective in reducing the Fludarabine-induced CD4+ cell depletion. *Blood* 90 (10), Suppl 1, 511a
39. Fenchel K., Hoffmann R., Borghardt J., Kirchner H., Pralle H., Ganser A., Atzpodien J.: Interleukin-2 reduces the CD 4+ cell depletion following Fludarabine and Idarubicin combination. *Br. J. Haematology* 102 (1998), 89
40. Atzpodien J., Borghardt E., Dreher K., Schrader A., Ganser A., Pralle H., Fenchel K.: Fludarabine and idarubicin followed by IL-2 in pretreated advanced indolent lymphoma: results of a phase II study. *Ann. Hematology* 77suppl. 1 (1998), A6
41. Fenchel K., Lassmann S., Borghardt E., Dreher K., Ganser A., Pralle H., Atzpodien J.: Fludarabine and idarubicin followed by IL-2 in the treatment of pretreated advanced indolent lymphoma: results of a phase II study. *Ann. Hematology* 77suppl. 2 (1998), S147

42. Fenchel K., Karthaus M., Steffens C., Dreher K., Böhme V., Pralle H., Kubicka S., Weber C., Stoffregen C.: Taxanes: an effective 2nd line treatment of advanced esophageal cancer – a randomised trial. Proc. of the American Society of Clinical Oncology ASCO, 18 (1999), 283a
43. Fenchel K., Winkler L., Pralle H., Kemkes-Matthes B.: Does therapy with G-CSF in haematological diseases cause coagulation activation? Proc. 5th international symposium on thrombotic diseases, Cannes, 6/98
44. Fenchel K., Lassmann S., Borghardt E., Dreher K., Ganser A., Pralle H., Atzpodien J.: Fludarabine and idarubicin followed by IL-2 in the treatment of pretreated advanced indolent lymphoma: results of a phase II study. Ann. Oncology 10 suppl. 3 (1999), 131
45. Fenchel K., Ehlers S., Matzdorff A., Nees M., Pralle H., Kemkes-Matthes B.: Tissue factor in myeloid leukemia. Ann. Hematolog. (2000) 79suppl. I, A70
46. Fenchel K., Ehlers S., Winkler L., Pralle H., Kemkes-Matthes B.: Does therapy with G-CSF in haematologic diseases cause coagulation activation? Proc. 6th International symposium on thrombotic diseases, Lisbon, 6/99
47. Fenchel K., Pralle H.: Prophylaxis of pulmonary mycosis with itraconazole solution in patients undergoing aggressive chemotherapy for AML, M. Hodgkin, NHL, CML and ALL. Proc. 6th international conference on the management of serious fungal infections, in press
48. Fenchel K., Goerg A., Matzdorff A., Nees M., Kemkes-Matthes B.: Tissue factor elevation in acute myeloid leukemia: prognostic value for leukemic cells? Blood 96,11 (2000), 201b
49. Bermann L., Fenchel K., Jahn B., Mitrou PS.: Up-regulation of adhesion molecules and secondary cytokines in cancer patients treated with bolus infusion II-2.

Am. Soc. Cancer Res., San Diego, USA, 20. – 23.5.1992

50. **Bergmann L., Fenchel K., Wijermans P., Engert A., Pralle H., Mitrou P.S., Diehl V., Hoelzer D.: Clinical experience with and immunosuppressive effects of fludarabine phosphate in pretreated advanced chronic lymphocytic leukemia. Onkol. 16 Suppl.1 (1993), 13**
51. **Bermann L., Heil G., Fenchel K., Brücher J., Bunjes D., Lohmeyer J., Gunsilius E., Mitrou P.S.: Interleukin-2 bolus infusion as late consolidation therapy in 2nd remission of acute myelocytic leukemia with and without autologous bone marrow transplantation – biological effects and first clinical results. Ann. Hematol. 64Suppl. (1992), Abstr.87**
52. **Göke B., Fenchel K., Knobloch S., Koop I., Adler G., Arnold R.: Influence of asperlicin, a CCK-antagonist, on the trophic response of the rat pancreas to protease-inhibitor feeding. Dig.Dis.Sciences (1987) 32;10:1167**
53. **Bergmann L., Fenchel K., Enzinger H.M., Jahn B., Weidmann E., Mitrou P.S.: Daily alternating schedule with interferon-alpha and interleukin-2 in advanced renal cell cancer – clinical results and biological effects. Eur.J.Cancer, 27 Suppl.2 (1991), 100 (Abstr.584)**
54. **Jahn B., Weidmann E., Bergmann L., Stock J., Kirsten R., Fenchel K., Mitrou P.S.: Secondary release of cytokines during interleukin-2 therapy in cancer patients. Onkol. 14 Suppl.2 (1991), 190 (Abstr.547)**
55. **Bergmann L., Fenchel K., Martin H., Jahn B., Mitrou P.S., Hoelzer D.: Interleukin-2 as late consolidation therapy in 2nd remission of acute myelocytic leukemia with and without autologous bone marrow transplantation. Onkol. 14 Suppl.2 (1991), 13 (Abstr.31)**
56. **Jahn B., Fenchel K., Bergmann L., Mitrou P.S.: Interleukin-2 inhibits interferon-alpha induced transcription of transforming growth factor-beta₁ in vivo. 8. Frühjahrstagung Dtsch. Ges.Immunol., München, 9. – 11.3.1992**
57. **Jahn B., Weidmann E., Bergmann L., Fenchel K., Mitrou P.S.: Induction of endogeneous interleukin-2 therapy. J. Cancer Res.Clin.Oncol. 118 (1992), R49**

58. **Bergmann L., Fenchel K., Mitrou P.S.: Consecutive studies with dose reduction using a daily alternating schedule of interferon-alpha and interleukin-2 in renal cell cancer. J. Cancer Res. Clin. Oncol. 118 (1992), R116**

59. **Bergmann L., Fenchel K., Heil G., Kolbe K., Martin H., Lengfelder E., Bunjes D., Lohmeyer J., Gunsilius E., Mitrou P.S.: Interleukin-2 as late consolidation therapy in 1st relapse of acute myelocytic leukemia – Preliminary results of a multicenter phase II study. Onkol. 15 (1992), Suppl.1, 27**

60. **Enzinger H.-M., Bergmann L., Fenchel K., Neugebauer T., Jahn B., Mitrou P.S.: Daily alternating schedules of interferon-alpha and interleukin-2 in advanced renal cell cancer – clinical results and biological effects. Onkol. 15 (1992), Suppl.1, 24**

61. **Brieger J., Weidmann E., Fuck S., Fenchel K., Mitrou P.S., Hoelzer D., Bergmann L.: Expression of the wilms tumor gene (wt-1) in human leukemias may provide early detection of minimal residual disease. Ann. Hematol. 67 Suppl. (1993), A15**

62. **Brieger J., Weidmann E., Fenchel K., Mitrou P.S., Bergmann L., Hoelzer D.: The wilms tumor gene (wt-1) mRNA is frequently expressed in AML and may provide early diagnosis of residual blasts. Proc. Am. Ass. Cancer Res. 35 (1994),223**

63. **Brieger J., Weidmann E., Fenchel K., Mitrou P.S., Bergmann L., Hoelzer D.: The wilms tumor gene wt-1 in acute myelogenous leukemia and it's possible relevance for the patient's prognosis. Brit. J. Haematol. 87 Suppl. 1, (1994), 4**

64. **Mitrou P.S., Enzinger H.-M., Fenchel K., Neugebauer T., Jahn B., Bergmann L.: Clinical results and biological effects of two dose modified daily alternating schedules with interferon-alpha and interleukin-2 in advanced renal cell cancer. Ann. Hematol. 65 Suppl. (1992), A94**

65. **Brieger J., Weidmann E., Fenchel K., Fuck S., Mitrou P.S., Bergmann L., Hoelzer D.: The wilms tumor gene as a new possible genetic marker in the detection of minimal residual disease in acute myelogenous leukemia. Cancer Res. Clin. Oncol. 129 Suppl.**

(1994) R106

66. **Jahn B., Bergmann L., Fenchel K., Weidmann E., Schwulera U., Mitrou P.S.: Cloning of peripheral lymphocytes in acute phase of acute myelocytic leukemia results in predominantly CD3⁺CD4⁺ T-cell Onkol. 15 (1992), Suppl. 1, 19**
67. **Jahn B., Fenchel K., Bergmann L., Mitrou P.S.: Interferon-alpha (IFN-alpha) induced transcription of transforming growth factor-beta₁ (TGF-beta) is Onkol. 15 (1992), Suppl. 1, 25**
68. **Jahn B., Fenchel K., Bergmann L., Mitrou P.S.: Interleukin-2 inhibits interferon-alpha induced transcription of transforming growth factor-beta₁ in vivo. 8th International Congress of Immunology, Budapest, 23. – 28.8.1992**
69. **Jahn B., Fenchel K., Bergmann L., Mitrou P.S.: Transforming growth factor-beta₁ (TGF-beta₁) in vivo: Increase of TGF-beta₁ specific mRNA by interferon-alpha (rIFN-alpha) is suppressed by interleukin2 (rIL-2) administration. 24th Congress Intern.Soc.Haematol., London, 23-27.8.1992**
70. **Bergmann L., Jahn B., Heil G., Kolbe K., Fenchel K., Mitrou P.S.: the effect of interleukin-2 in the consolidation of AML in 2nd remission may be caused by the activation of specific autologous CD4* cytotoxic T-cells 24th Congress Intern.Soc.Haematol., London, 23-27.8.1992**
71. **Bergmann L., Karacas T., Jahn B., Lautenschläger G., Szepesi S., Fenschel K., Hoelzer D., Mitrou P.S.: Intensive chemotherapy with vincristine, high-dose adriamycin, cyclophosphamide, prednisone and etoposide (VACPE) in high-malignant non-Hodgkin lymphomas. – An ongoing phase II trial. Ann.Hematol.65 suppl. (1992), A35**
72. **Jahn B., Bergmann L., Fenchel K., Weidmann E., Schwulera U., P.S. Mitrou: CD3⁺ CD4⁺ T-cells as effective cells of autologous blase specific cytotoxicity in acute myelocytic leukemia. Ann.Hematol. 65 Suppl. (1992), A73**

73. **Brieger J., Jahn B., Fenchel K., Appelhans, Bergmann L., Mitrou P.S.: Expression of transforming growth factor- β 1 and interleukin-10 mRNA indicate immunosuppressive potential of AML blasts.
Ann.Hematol 65 suppl. (1992), A40**
74. **Jahn B., Fenchel K., Bergmann L., Mitrou P.S.: Interferon-alpha induced transcription of transforming growth factor- β 1 is impaired by interleukin-2 in vivo.
Ann.mematol. 65 Suppl. (1992), A73**
75. **Jahn B., Bergmann L., Fenchel K., Weidmann E., Schwulera U., P.S. Mitrou: Cloning of peripheral lymphocytes in acute phase of acute myelocytic leukemia results in predominantly CD4+ CD8+ T-cell clones with blast specific autologous cytotoxicity.
Blood 80 Suppl. 1 (1992), 188a**
76. **Bergmann L., Knuth A., Lautenschläger G., Karacas T., Jahn B., Szepesi S., Fenchel K., Mitrou P.S., Hoelzer D.: Intensivierte Chemotherapie mit Vincristin, Hochdosis-Adriablastin, Cyclophosphamid, Prednison und VP-16 (VACPE) bei hochmalignen non-Hodgkin Lymphomen- Zwischenergebnisse einer Phase II Studie
Med.Klinik 88 Suppl2 (1993), 215**
77. **Bergmann L., Knuth A., Lautenschläger G., Karacas T., Jahn B., Szepesi S., Fenchel K., Mitrou P.S., Hoelzer D.: Intensive chemotherapy with a combined therapy of vincristine, high-dose adriamycin, cyclophosphamide, prednisone in high-grade malignant lymphomas. – A phase II study, 5th International Conference on Malignant Lymphoma, Lugano, 9.-12.6.1993**
78. **Brieger J., Weidmann E., Fenchel K., Mitrou P.S., Hoelzer D.: Inversion of remission duration in 2nd remission of AML by interleukin-2. The antileucemic effect may be caused by autologous CD4+ Cytotoxic lymphocytes. Exp.Hematol. 21, (1993), 1046**
79. **Bergmann L., Jahn B., Heil G. Kolbe K., Lengfelder E., Lohmeyer J., Fenchel K., Weidmann E., Mitrou P.S., Hoelzer D.: Inversion of remission duration in 2nd remission of AML by interleukin-2. the antileucemic effect may be caused by autologous CD4+ cytotoxic lymphocytes. Exp.Hematol. 21, (1993), 1046**

80. Brieger J., Weidmann E., Fenchel K., Mitrou P.S., Hoelzer D., Bergmann L.: Transforming growth factor transcription and release by AML blasts may indicate immunosuppressive potential. *Exp. Hematol.* 21, (1993), 1115
81. Brieger J., Weidmann E., Fenchel K., Mitrou P.S., Hoelzer D., Bergmann L.: Transforming growth factor (TGF- β 1) transcription and release by leukemic cells may provide an explanation for immunosuppression in leukemia. *Ann. Hematol.* 67 Suppl. (1993), A15
82. Mitrou P.S., Jahn B., Bergmann L., Fenchel K., Weidmann E., Schwulera U., Hoelzer D.: Cloning of peripheral lymphocytes in untreated acute myelocytic leukemia results in predominantly CD3⁺ CD4⁺ T-cell clones with blast specific autologous cytotoxicity. *Ann. Hematol.* 67 Suppl. (1993), A82
83. Weidmann E., Brieger J., Fenchel K., Hoelzer D., Bergmann L., Mitrou P.S.: Introduction of a model to study the in vitro T-cell response to autologous cytokine gene engineered tumor cells. *Ann. Hematol.* 67 Suppl. (1993), A82
84. Bergmann L., Karacas T., Knuth A., Lautenschläger G., Szepesi S., Fenchel K., Mitrou P.S., Hoelzer D.: Effective chemotherapy with a combined therapy of vincristine, adriamycin, cyclophosphamide, prednisone and etoposide (VACPE) in high-grade non-hodgkin lymphomas. – Results of a phase II study. *Ann Hematol.* 67 Suppl. (1993), A9
85. Bergmann L., Karacas T., Knuth A., Lautenschläger G., Szepesi S., Fenchel K., Mitrou P.S., Hoelzer D.: Combined therapy with vincristine, Adriamycin, cyclophosphamide, prednisone and etoposide (VACPE) in high-grade malignant lymphomas. – Results of a phase II study. *Cancer Res. Clin. Oncol.* 129 Suppl. (1994) R31

86. Weidmann E., Brieger J., Fenchel K., Mitrou P.S., Bergmann L., Hoelzer D.: Expression of the IL-2 receptor alpha, beta, gamma chains on AML blasts and on AML derived cell lines. *Proc. Am. Ass. Cancer Res.* 35 (1994), 531
87. Schui D.K., Brieger J., Weidmann E., Fenchel K., Mitrou P.S., Bergmann L., Hoelzer D.: The inhibition of the lymphokine activated killer cells activation mediated by AML culture supernatants might be due to transforming growth factor beta (TGF- β 1). *Ann. Hematol.* 68 Suppl. 1 (1994), A37
88. Brieger J., Weidmann E., Fenchel K., Mitrou P.S., Bergmann L., Hoelzer D.: The amplification of the wilms tumor gene (wt-1) mRNA using the polymerase chain reaction technique (PCR) may enable sensitive detection of small blast populations in AML. *Ann. Hematol.* 68 Suppl. 1 (1994), A16
89. Weidmann E., Brieger J., Fenchel K., Hoelzer D., Bergmann L., Mitrou P.S.: IL-2 receptor (IL-2R)alpha, beta, gamma chains expressed on blasts of acute myelocytic leukemia may not be functional. *Ann. Hematol.* 68 Suppl. 1 (1994), A21
90. Weidmann E., Brieger J., Jahn B., Fenchel K., Bergmann L., Hoelzer D., Mitrou P.S.: Analysis of lymphocyte mediated cytotoxic activity against blast cells from acute myelocytic leukemia by blast cell lactate dehydrogenase release. *Brit. J. Haematol.* 87 Suppl. 1, (1994), 23
91. Schui D. K., Brieger J., Weidmann E., Fenchel K., Mitrou P.S., Hoelzer D., Bergmann L.: TGF-beta1 might be responsible for the inhibition of LAK activity mediated by blast cell culture supernatants. *Brit. J. Haematol.* 87 Suppl. 1, (1994), 20
92. Brieger J., Weidmann E., Fuck S., Fenchel K., Bergmann L., Hoelzer D., Mitrou P.S.: Unresponsiveness to IL-2 by AML blast cells expressing IL-2 receptors. *Onkol.* 17 Suppl. 2, (1994), 17
93. Borghardt E.J., Kirchertz E.J., Marten I., Fenchel K.: Protein A-immunoadsorption in

chemotherapy associated hemolytic-uremic syndrome. Kongreß Dresden 4/97

- 94. Karthaus M., Rosenthal C., Paul H., Novotny J., Hübner G., Fenchel K. Geissler RG., Hertenstein B., Ganser A.: Effect of topical oral G-CSF application on oral mucositis in high-grade lymphoma patients treated with HD-methotrexate (HD-MTX) – results of a randomized placebo-controlled trial. Proc. of the American Society of Clinical Oncology ASCO, 17 (1998), 61a**

- 95. Georg A., Matzdorff A., Fenchel K., Kemkes-Matthes B., Pralle H.: Quantification of tissue factor antigen expression on monocytes and neutrophils in healthy volunteers and in AML patients. Blood 96,11 (2000), 75b**

- 96. Georg A., Matzdorff A., Fenchel K., Kemkes-Matthes B., Pralle H.: Quantification of tissue factor antigen expression on monocytes and neutrophils in healthy volunteers and in AML patients. Blood 96, 11 (2000), 75b**

- 97. Aldulak-Tursun C., Fenchel K., Matzdorff A., Pralle H., Kemkes-Matthes B.: Frequency of thromboembolic complications in cancer patients. GTH, Freiburg 2001**

- 98. Rudolph S., Fahlke J., Kuhn R., Fenchel K., Lippert H., Ridwelski K.: Randomised trial with or without Amifostine to reduce neurotoxic side effects under chemotherapy with Oxaliplatin (L-OHP), FA/5-FU. Proc. of the American Society of Clinical Oncology ASCO, 20 (2001), 302b**

Wertung der Arbeiten wie folgt: die abstracts 1-50 entstammen meinen ureigensten Arbeiten im Sinne der Urheberschaft und Durchführung, die abstracts 51 – 65 beinhalten einen 40 %igen Eigenanteil und die Arbeiten 66 – 98 ca. 10 – 20 %.